<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Ultraconserved region 339 modulation of tumor suppressor microRNAs in cancer" Version="20180509" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">The TP53-uc.339-miRNA-CCNE2 network. TP53 directly inhibits the expression of ultraconserved region 339 (us339). Ultraconserved region 339 functions as an &#8220;entrapper&#8221; for CCNE2 targeting miR-339, -663b, and -95 leading to up-regulation of CCNE2 and increased tumor growth and migration.</Comment>
  <BiopaxRef>a6d</BiopaxRef>
  <Graphics BoardWidth="802.0000000000001" BoardHeight="698.0000000000001"/>
  <DataNode TextLabel="uc339&#10;(Entraper1)" GraphId="f219e" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="TP53" GraphId="fdf54" Type="GeneProduct">
        </DataNode>
  <DataNode TextLabel="MIR95" GraphId="d7b8a" Type="Rna" GroupRef="ddb77">
    <Graphics Color="cc00cc"/>
    </DataNode>
  <DataNode TextLabel="MIR339" GraphId="ef0cb" Type="Rna" GroupRef="ddb77">
    <Graphics Color="cc00cc"/>
    </DataNode>
  <DataNode TextLabel="MIR663B" GraphId="c6483" Type="Rna" GroupRef="ddb77">
    <Graphics Color="cc00cc"/>
    </DataNode>
  <DataNode TextLabel="CCNE2" GraphId="e540f" Type="GeneProduct">
        </DataNode>
  <State GraphRef="fdf54" TextLabel="" GraphId="d0d47">
    <Graphics ShapeType="Hexagon"/>
    </State>
  <Interaction>
    <Graphics Color="ff0000">
      <Point GraphRef="f219e"/>
      <Point GraphRef="d65e7" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction>
    <Graphics>
      <Point GraphRef="fdf54"/>
      <Point GraphRef="f219e" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction>
    <Graphics LineStyle="Broken">
      <Point GraphRef="d65e7"/>
      <Point GraphRef="e540f" ArrowHead="mim-inhibition"/>
    </Graphics>
    </Interaction>
  <Interaction>
    <Graphics>
      <Point GraphRef="e540f"/>
      <Point GraphRef="a34ce" ArrowHead="Arrow"/>
    </Graphics>
    </Interaction>
  <GraphicalLine GroupRef="c3466">
    <Graphics Color="ff0000">
      <Point/>
      <Point ArrowHead="mim-inhibition"/>
    </Graphics>
  </GraphicalLine>
  <Label TextLabel="Inactivating mutation" GraphId="a0820" GroupRef="c3466">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="Increased tumor &#10;growth and motility" GraphId="a34ce">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Label TextLabel="Entrapping" GraphId="c1044" GroupRef="c3466">
    <Graphics FillColor="ffffff"/>
  </Label>
  <Shape TextLabel="Legend" GraphId="d5d02" GroupRef="c3466">
    <Graphics Align="Left" ShapeType="Rectangle"/>
  </Shape>
  <Shape GraphId="dda66" GroupRef="c3466">
    <Graphics ShapeType="Hexagon"/>
  </Shape>
  <Group GroupId="c3466" Style="Group"/>
  <Group GroupId="ddb77" GraphId="d65e7" Style="Group"/>
  <InfoBox/>
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a6d">
      <bp:ID >29180617</bp:ID>
      <bp:DB >PubMed</bp:DB>
      <bp:TITLE >Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs.</bp:TITLE>
      <bp:SOURCE >Nat Commun</bp:SOURCE>
      <bp:YEAR >2017</bp:YEAR>
      <bp:AUTHORS >Vannini I</bp:AUTHORS>
      <bp:AUTHORS >Wise PM</bp:AUTHORS>
      <bp:AUTHORS >Challagundla KB</bp:AUTHORS>
      <bp:AUTHORS >Plousiou M</bp:AUTHORS>
      <bp:AUTHORS >Raffini M</bp:AUTHORS>
      <bp:AUTHORS >Bandini E</bp:AUTHORS>
      <bp:AUTHORS >Fanini F</bp:AUTHORS>
      <bp:AUTHORS >Paliaga G</bp:AUTHORS>
      <bp:AUTHORS >Crawford M</bp:AUTHORS>
      <bp:AUTHORS >Ferracin M</bp:AUTHORS>
      <bp:AUTHORS >Ivan C</bp:AUTHORS>
      <bp:AUTHORS >Fabris L</bp:AUTHORS>
      <bp:AUTHORS >Davuluri RV</bp:AUTHORS>
      <bp:AUTHORS >Guo Z</bp:AUTHORS>
      <bp:AUTHORS >Cortez MA</bp:AUTHORS>
      <bp:AUTHORS >Zhang X</bp:AUTHORS>
      <bp:AUTHORS >Chen L</bp:AUTHORS>
      <bp:AUTHORS >Zhang S</bp:AUTHORS>
      <bp:AUTHORS >Fernandez-Cymering C</bp:AUTHORS>
      <bp:AUTHORS >Han L</bp:AUTHORS>
      <bp:AUTHORS >Carloni S</bp:AUTHORS>
      <bp:AUTHORS >Salvi S</bp:AUTHORS>
      <bp:AUTHORS >Ling H</bp:AUTHORS>
      <bp:AUTHORS >Murtadha M</bp:AUTHORS>
      <bp:AUTHORS >Neviani P</bp:AUTHORS>
      <bp:AUTHORS >Gitlitz BJ</bp:AUTHORS>
      <bp:AUTHORS >Laird-Offringa IA</bp:AUTHORS>
      <bp:AUTHORS >Nana-Sinkam P</bp:AUTHORS>
      <bp:AUTHORS >Negrini M</bp:AUTHORS>
      <bp:AUTHORS >Liang H</bp:AUTHORS>
      <bp:AUTHORS >Amadori D</bp:AUTHORS>
      <bp:AUTHORS >Cimmino A</bp:AUTHORS>
      <bp:AUTHORS >Calin GA</bp:AUTHORS>
      <bp:AUTHORS >Fabbri M</bp:AUTHORS>
    </bp:PublicationXref>
  <bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"><bp:TERM>microRNA pathway</bp:TERM><bp:ID>PW:0000808</bp:ID><bp:Ontology>Pathway Ontology</bp:Ontology></bp:openControlledVocabulary><bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"><bp:TERM>cancer pathway</bp:TERM><bp:ID>PW:0000605</bp:ID><bp:Ontology>Pathway Ontology</bp:Ontology></bp:openControlledVocabulary><bp:openControlledVocabulary xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"><bp:TERM>cancer</bp:TERM><bp:ID>DOID:162</bp:ID><bp:Ontology>Disease</bp:Ontology></bp:openControlledVocabulary></Biopax>
</Pathway>